Lv6
1910 积分 2021-10-22 加入
Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization
5小时前
已完结
Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization
1个月前
已完结
The changing therapeutic landscape of head and neck cancer
1个月前
已完结
Small Cell Lung Cancer: A Review
3个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC
6个月前
已完结
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer
6个月前
已完结
Biomarkers of Hyperprogression and Pseudoprogression with Immune Checkpoint Inhibitor Therapy
6个月前
已关闭
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial
7个月前
已完结
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
7个月前
已完结
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
7个月前
已完结
皖公网安备34019202002308
